- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
NuLife Sciences announced it is initiating the second round of pre-clinical surgeries to refine the NuLife Technique through their subsidiary.
NuLife Sciences (OTCQB:NULF) announced it is initiating the second round of pre-clinical surgeries to refine the NuLife Technique through their subsidiary.
As quoted in the press release:
The series of surgeries build upon each other, and are part of the pre-clinical trial of the NuLife Technique, which commenced on August 8th at Florida International University, to evaluate the NuLife process and prove that the NuLife Technique is viable and effective.
This surgery, which is being conducted by Doctors Juan Arenas and Tjasa Hranjec, will serve to confirm results seen in the first surgery, as well as an opportunity to fine tune the NuLife Technique. Juan Arenas, MD, FACS, MBA, is a board-certified transplant surgeon, Director of the Solid Organ Transplant Institute, and the Chair of Solid Organ Transplant at Memorial Regional Hospital in Hollywood, Florida. Prior to this role, he served as the Chief of the Division of Surgical Transplantation at the University of Texas (UT) Southwestern Medical Center for the past 10 years. Tjasa Hranjec, MD, MS-CR is a Board certified trauma/critical care and transplant surgeon, the director of the Transplant Intensive Care Unit at the Memorial Regional Hospital in Hollywood.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.